Services

Header

Header

Header

Custom Multiepitope Peptide Synthesis

Engineered multiepitope peptide constructs that integrate antigenic, receptor-binding, targeting, or other functional peptide domains into a single sequence-defined molecule for vaccine research, immunology, diagnostics, and therapeutic discovery.

Lysine-Based Dendrimers Linear & Branched Formats MAP-Based Architectures Custom Linkers Modification & Conjugation Purification & Analytical Characterization

Why Researchers Choose Multiepitope Peptides

Multiepitope peptides integrate two or more biologically relevant sequences into a single engineered construct. They are well suited for research programs that must address multiple antigenic regions, immune-cell targets, sequence variants, or functional domains without manufacturing and qualifying a separate peptide for every target.

Compared with synthesizing, characterizing, and managing multiple individual peptides, a sequence-defined multiepitope construct can streamline experimental workflows while enabling coordinated presentation of B-cell, CD4+ T-cell, CD8+ T-cell, targeting, or other functional domains. Sequence order, spacing, linker identity, terminal chemistry, and optional functional components can be engineered as part of one integrated molecule.

Bio-Synthesis supports the complete design-to-product pathway, including custom peptide synthesis, epitope arrangement, linker engineering, sequence feasibility review, purification, modification, peptide bioconjugation and fit-for-purpose analytical characterization.

Engineering a sequence-defined multiepitope peptide construct Functional peptide modules are selected, connected through linker engineering, evaluated as linear, branched, MAP, or hybrid architectures, and manufactured as one sequence-defined construct. MULTIEPITOPE CONSTRUCT ENGINEERING From functional modules to one manufacturable, sequence-defined molecule 1 SELECT FUNCTIONAL MODULES B-Cell Epitope CD4+ T-Cell Epitope CD8+ T-Cell Epitope Targeting Domain Functional Module 2 ENGINEER THE INTERFACES Linker Strategy Order & Spacing Solubility & Synthesis 3 SELECT THE ARCHITECTURE Linear Branched MAP Hybrid ONE SEQUENCE-DEFINED MULTIEPITOPE PEPTIDE CONSTRUCT
Custom engineered Manufacturability reviewed Purification planned Analytically characterized

Broader Biological Coverage

Integrate multiple antigenic, variant-specific, targeting, or functional regions within one construct.

Streamlined Experimental Workflow

Reduce the need to manufacture, qualify, and handle multiple individual peptides.

Flexible Molecular Engineering

Engineer epitope order, linker identity, spacing, terminal chemistry, and optional functional components.

Defined Construct Manufacturing

Manufacture one sequence-defined construct with project-appropriate purification, analytical characterization, documentation, and packaging.

Single Peptide, Multiepitope Peptide and MAP Peptide Compared

These peptide formats address different scientific objectives. The comparison below distinguishes sequence diversity, epitope valency, scaffold architecture, and principal engineering considerations.

Feature Single peptide Multiepitope peptide Conventional MAP peptide
Primary purpose Study one defined sequence or motif Combine different epitopes or functional domains Increase display density of one or a few sequences
Sequence diversity One sequence Two or more distinct sequences Often repeated copies of one epitope
Typical architecture Linear or cyclic Linear, branched, MAP-based or conjugated Lysine dendrimer scaffold, commonly MAP2, MAP4 or MAP8
Primary engineering considerations Sequence, termini and modifications Order, junctions, linker design, processing and manufacturability Valency, branch completeness and epitope density
Typical applications Assays, standards, substrates and single-epitope studies Vaccine, immune-monitoring, diagnostic and multifunctional research Carrier-free immunization and high-density antigen display

Interactive Multiepitope Peptide Selection Guide

Choose a format based on the research goal, epitope class, total construct length, accessibility, processing requirements and downstream use. Each option combines application guidance with architecture, risk, design and QC considerations.

Linear Multiepitope Peptide

Different epitopes are joined sequentially in one peptide chain using direct junctions or designed spacers.

Defined sequence order Single-chain product Processing studies
Best Fit

Moderate total length and a clear need for sequential epitope presentation.

Main Risk

Hydrophobicity, secondary structure and junctional epitopes increase with length.

Design Focus

Order, linker identity, terminal caps and charge balance.

QC

HPLC/UPLC and mass spectrometry, where compatible with construct size.

Common Uses

Vaccine research, T-cell stimulation, immune monitoring and sequence-defined functional studies.

Design Consideration

Should epitopes remain linked, be separated by processing-oriented junctions or instead be supplied as individual peptides or a pool?

Branched Multiepitope Peptide

Distinct epitopes extend from defined branch points, allowing multiple sequences to be displayed without creating one very long linear chain.

Different arms Controlled branch points Improved display
Best Fit

Constructs needing simultaneous exposure of two or more different motifs.

Main Risk

Mixed-arm products and incomplete branch coupling.

Design Focus

Orthogonal protection, arm order and branch-core accessibility.

QC

Purity and mass confirmation with branch-aware interpretation.

Common Uses

Simultaneous display of multiple antigenic or functional motifs, antibody research and compact multi-arm designs.

Design Consideration

Do the epitopes need independent exposure, and can branch placement reduce the length or crowding of a linear construct?

MAP-Based Multiepitope Construct

A lysine dendrimer scaffold is adapted to display different epitopes rather than identical copies of one sequence.

Lysine core High-density display Carrier-free option
Best Fit

Immunogen or binding studies that benefit from multivalent presentation.

Main Risk

Steric crowding, solubility and purification complexity.

Design Focus

Valency, spacer length and epitope distribution.

QC

Fit-for-purpose purity and intact-mass characterization.

Common Uses

Vaccine research, carrier-free immunization, antibody generation and high-density antigen display.

Design Consideration

Is increased valency more important than preserving each epitope as a distinct, independently accessible sequence?

Multiepitope–Carrier Conjugate

The peptide construct is linked to KLH, BSA, OVA, CRM197 or another selected protein for immunization or assay use.

Immunogen design Orientation control Carrier selection
Best Fit

Antibody generation and workflows requiring a protein carrier.

Main Risk

Uncontrolled attachment can obscure epitopes or create heterogeneous loading.

Design Focus

Handle location, carrier choice and immunogen-versus-assay strategy.

QC

Peptide QC plus conjugate-specific characterization and documentation.

Common Uses

Antibody generation, ELISA antigen development and immunization workflows that require a protein carrier.

Design Consideration

Where should the conjugation handle be placed so the carrier does not mask a critical epitope or interfere with assay use?

Multiepitope Hybrid Construct

Epitopes are integrated with a peptide adjuvant, targeting motif, lipid, PEG, fluorophore, affinity tag or other functional component.

Targeting Adjuvant motif Label or cargo
Best Fit

Projects combining antigenic display with delivery, tracking or assay functionality.

Main Risk

Competing chemistry, steric effects and difficult purification.

Design Focus

Site specificity, linker orthogonality and order of assembly.

QC

Component-specific testing plus final intact-product analysis.

Common Uses

Diagnostic probes, receptor-binding studies, imaging, delivery and multifunctional therapeutic research.

Design Consideration

Which modification site preserves epitope accessibility while supporting the intended label, cargo, targeting or release function?

Design note: Epitope selection and architecture are application-specific. Final constructs should be reviewed for sequence feasibility, linker behavior, solubility, junctional epitopes, purification and analytical compatibility.

Multiepitope Construct Design Engineering

A multiepitope construct should be evaluated as one integrated engineered molecule rather than as a simple collection of individual peptide sequences.

Epitope Arrangement

Evaluate sequence order, orientation and spacing to support accessibility, processing and the intended biological readout.

01

Linker Engineering

Select flexible, rigid, protease-sensitive or custom junctions according to mobility, separation and release requirements.

02

Junction Epitope Control

Review new sequence junctions to reduce unintended recognition motifs, difficult cleavage sites or unwanted structural effects.

03

Construct Functionalization

Plan labels, affinity tags, lipids, PEG, click handles, isotopes or conjugation sites without compromising key epitopes.

04

Synthesis Feasibility

Assess total length, hydrophobicity, charge, cysteine content, aggregation risk and protection requirements before synthesis.

05

Analytical Strategy

Match HPLC/UPLC, mass spectrometry and complementary methods to construct size, branching and modification complexity.

06

Choosing Linkers for Multiepitope Peptide Constructs

Linkers influence flexibility, spacing, proteolytic processing, solubility and the possibility of creating unintended junctional epitopes. The examples below represent commonly used engineering approaches rather than universal design rules. Linker selection should be based on biological intent, steric requirements, processing behavior, synthetic accessibility, purification, and analytical feasibility.

GGGGS / (GGGGS)n

Flexible Linkers

Provide conformational freedom and physical separation between domains. Useful when accessibility is more important than a fixed orientation.

EAAAK

Rigid Linkers

Promote separation with lower flexibility and may reduce direct interaction between adjacent domains.

GPGPG

Proline-Rich Spacers

Often considered in vaccine-oriented constructs to separate epitopes and reduce structural coupling.

AAY

Processing-Oriented Junctions

May be evaluated where proteasomal processing or epitope liberation is part of the design hypothesis.

PEG / aminoalkyl

Non-Peptide Spacers

Hydrophilic synthetic spacers can increase distance, alter solubility or create a defined modification site.

Custom cleavable

Trigger-Responsive Linkers

Protease-sensitive, redox-sensitive or other cleavable designs can be considered when controlled release is required.

Important: A literature linker should not be selected by name alone. The complete sequence, neighboring residues, intended compartment, cleavage mechanism and synthesis constraints should be reviewed together.

Applications for Multiepitope Peptide Constructs

Vaccine Research

  • Multiepitope vaccine concepts
  • Cancer neoantigen constructs
  • Infectious-disease antigen designs

Immunology

  • B-cell and T-cell studies
  • ELISpot and stimulation assays
  • Immune monitoring and response profiling

Diagnostics

  • Exploratory ELISA antigens
  • Biomarker assay development
  • Variant and strain comparison

Therapeutic & Targeting Research

  • Receptor-targeting constructs
  • Multi-domain functional peptides
  • Delivery, imaging or conjugate research

Common Multiepitope Design and Manufacturing Challenges

A dendrimer project involves several separate design decisions. First select the chemical scaffold, then define the molecular architecture, add the required functional components, and establish a manufacturing and characterization strategy. Bio-Synthesis can evaluate these layers together rather than treating them as isolated modifications.

A

Excessive Total Length

Long constructs can suffer incomplete coupling, deletion products and difficult purification. Segmentation, ligation, branching or an alternative architecture may be needed.

B

Poor Solubility and Aggregation

Clusters of hydrophobic epitopes can reduce resin swelling, solubility and chromatographic recovery. Order changes, hydrophilic spacers or formulation planning may help.

C

Junctional Epitopes

New residue combinations at epitope boundaries may create unintended recognition motifs or alter processing. Junctions should be reviewed as part of the complete sequence.

D

Steric Interference

Adjacent epitopes can mask one another or adopt unwanted conformations. Linker length, rigidity and branch placement may need optimization.

E

Cysteine and Disulfide Management

Multiple cysteines increase oxidation, pairing and protection complexity. Orthogonal chemistry or controlled folding strategies may be required.

F

Analytical Characterization Challenges

Large, branched or heavily modified products may ionize poorly or generate multiple conformers. Complementary analytical methods may be needed beyond one MS readout.

G

Purification Difficulty

Closely related truncations and partially coupled species may be hard to resolve. Method development must account for size, charge and hydrophobicity.

H

Solubility and Formulation

A purified construct may still be difficult to dissolve at the required concentration. Counterion, buffer, pH and storage format should be planned early.

How Difficult Multiepitope Constructs Can Be Optimized

Optimization is project-specific. The strategies below show how common risks may be addressed during sequence review, architecture selection, synthesis planning and purification development.

Challenge Representative Engineering Strategies Planning Considerations
Aggregation or poor solubility Charge redistribution, hydrophilic spacers, PEG units or sequence reordering Changes should preserve epitope function and intended processing.
Steric interference Longer or more rigid spacers, altered orientation or branched display Accessibility must be balanced against added length and synthetic complexity.
Excessive linear length Branching, ligation, modular assembly or separate peptide pools The best strategy depends on whether a single intact construct is biologically required.
Cysteine or disulfide complexity Orthogonal protection, selective oxidation or cysteine repositioning Native disulfide requirements should be defined before synthesis.
Closely related impurities Alternative protecting-group strategy, optimized coupling and multidimensional purification Purity targets should reflect construct complexity and downstream use.
Poor epitope accessibility Spacer redesign, branch relocation or terminal reorientation Structural assumptions should be confirmed experimentally when possible.

From Design Review to a Well-Characterized Construct

Sequence & Feasibility Review

Evaluate total length, composition, epitope order, linker choices, modification sites and likely synthesis risks.

01

Architecture & Linker Engineering

Select a linear, branched, MAP-based or conjugated format and define the assembly, protection and junction strategy.

02

Purification Strategy

Develop preparative HPLC and complementary methods according to size, charge, solubility and product heterogeneity.

03

Analytical Characterization

Confirm identity, purity, molecular integrity, and project-specific quality attributes using methods selected for the construct architecture and physicochemical properties.

04

Typical Specifications and Available Options

Design Element Available Options Planning Notes
Construct Format Linear Branched MAP-Based Conjugated Selected according to length, display, processing and intended application.
Epitope Types B-cell, CD4+ T-cell, CD8+ T-cell, antigenic regions, variants and functional motifs Sequences should be supplied with desired order or architecture.
Linkers Flexible, rigid, protease-sensitive, hydrophilic spacers and custom junctions Compatibility depends on the biological and synthetic objective.
Modifications Terminal caps, PEG, lipids, dyes, affinity tags, click handles and isotopic labels Site-specific placement should be defined during design review.
Purification Preparative RP-HPLC, ion-exchange, SEC or project-specific combinations Method selection depends on size, charge, solubility and heterogeneity.
Analytical Characterization Analytical HPLC/UPLC, mass spectrometry, where compatible, purity assessment and COA Additional analytical methods can be incorporated according to construct complexity, physicochemical behavior, and project-specific requirements.
Scale Research-scale synthesis through larger-scale custom manufacturing Final scale is subject to feasibility, architecture and purity requirements.

Analytical Strategy for Complex Peptide Constructs

Analytical methods are selected according to construct architecture, molecular complexity, physicochemical behavior, and project-specific requirements. No single analytical method is universally suitable for every multiepitope construct.

Method Primary Purpose When It Is Most Useful
Analytical HPLC/UPLC Purity assessment and chromatographic profile Routine release testing and comparison of closely related product species.
Mass Spectrometry Identity and intact-mass confirmation Linear, branched and modified constructs when ionization and mass range are suitable.
Size-Exclusion Chromatography Assessment of aggregation or higher-molecular-weight species Larger constructs, peptide–protein conjugates and aggregation-prone products.
UV/Visible Spectroscopy Concentration, chromophore content or dye loading Fluorescent, chromogenic or otherwise UV-active conjugates.
Amino Acid Analysis Composition and quantitative support Projects requiring orthogonal compositional or concentration data.
Conjugation-Specific Testing Loading, labeling ratio or component incorporation Peptide–protein, peptide–oligonucleotide, polymer and small-molecule conjugates.

Planning note: Analytical characterization confirms chemical identity, purity and selected product attributes. Biological activity assays are separate studies and should be defined according to the intended research application.

Extend Multiepitope Peptides with Functional Components

Multiepitope peptide constructs can be engineered with site-specific labels, spacers, conjugation handles, targeting modules, lipids, polymers, or other functional components when these elements are incorporated into the overall architecture and feasibility review.

Fluorescent Dyes

Site-defined labels for imaging, binding and assay development.

Stable Isotopes

Heavy amino acids for quantitative LC-MS and reference standards.

PEG and Hydrophilic Spacers

Spacing, solubility and conjugation options using defined PEG lengths.

Glycosylation

Site-specific carbohydrate incorporation for glycoepitope research.

Click and Reactive Handles

Azide, alkyne, amino, thiol and other orthogonal functional groups.

Bioconjugation

Peptide-protein, peptide-oligonucleotide, polymer and small-molecule conjugates.

Why Choose Multiepitope Peptides?

Multiepitope peptides offer a chemically defined alternative for many exploratory immunology and therapeutic discovery programs where rapid design iteration and precise sequence control are important.

Multiepitope Peptides Protein / Recombinant Constructs
Precisely defined chemical sequence Biological expression systems
Rapid design optimization Longer construct optimization
Straightforward site-specific modification Modification often requires protein engineering
Flexible linker engineering and conjugation chemistry More limited post-expression modification
Ideal for epitope-focused studies Useful for full-length protein investigations

Information That Helps Expedite Project Review

Providing the information below allows a more efficient feasibility review and helps align architecture, synthesis, purification and analytical planning with your intended application.

Complete epitope sequences or target regions

Desired epitope order, orientation or branch arrangement

Preferred linker or processing strategy

Required labels, tags, cargo or conjugation handles

Target quantity and purity specification

Required analytical methods and documentation

Desired formulation, counterion or storage format

Intended research application and downstream assay

Pre-quote design review available: Bio-Synthesis can evaluate epitope order, linker strategy, junctions, solubility, synthesis feasibility, purification and analytical characterization before quotation.

Need help designing a multiepitope peptide construct?

Provide the target antigen or protein, proposed epitope sequences, preferred construct architecture, linker strategy, desired modifications or conjugation chemistry, target quantity, purity requirements, analytical expectations, and project timeline. Bio-Synthesis can review epitope arrangement, synthetic accessibility, purification strategy, analytical characterization, and the most appropriate manufacturing approach.

What to Send

  • Target antigen or protein
  • Desired epitope sequences
  • B-cell, CD4+ or CD8+ epitopes
  • Preferred linker strategy
  • Target quantity, purity, and analytical requirements
  • Desired modifications or conjugation chemistry
  • Analytical expectations and project timeline

What We Review

Our scientists review epitope arrangement, linker selection, construct architecture, synthesis feasibility, purification strategy, analytical characterization and optional functional modifications to help optimize manufacturability and downstream performance.

Quality Systems & Manufacturing Support

QMS

ISO-Supported Peptide Manufacturing

Custom multiepitope peptide constructs, branched peptides, modified peptides, and peptide conjugates supported by controlled synthesis, purification, analytical characterization, documentation, and project-specific packaging.

ISO 9001:2015 Quality management system
ISO 13485:2016 Medical-device quality framework
ISO 14001 Environmental management system
Analytical Characterization HPLC/UPLC, mass spectrometry, where compatible, purity assessment and COA

FAQ

What is a multiepitope peptide?
A multiepitope peptide is a sequence-defined construct containing two or more different epitope or functional peptide sequences. It may be linear, branched, MAP-based or conjugated to another component.
How is a multiepitope peptide different from a MAP peptide?
A conventional MAP peptide commonly presents several copies of one epitope on a lysine scaffold. A multiepitope peptide combines different epitopes, although a MAP scaffold may also be adapted to display different sequences.
Why use a multiepitope peptide instead of several individual peptides?
A multiepitope construct can combine several targets in one defined molecule, simplify handling and enable controlled order, spacing and functionalization. Separate peptides may still be preferable when each epitope must be tested independently or supplied as a pool.
Can adjuvant, targeting or imaging components be incorporated?
Peptide adjuvants, targeting sequences, lipids, PEG, fluorophores, affinity tags and conjugation handles may be incorporated when compatible with the design and synthesis strategy.
How are difficult multiepitope constructs purified?
Purification is selected according to size, charge, hydrophobicity and heterogeneity. Preparative RP-HPLC may be combined with ion-exchange or size-based methods where appropriate.
What analytical methods are available?
Typical characterization may include analytical HPLC/UPLC and mass spectrometry. Additional methods are selected according to construct size, composition and intended use.
What information is needed for a quotation?
Provide the complete sequence or epitope list, desired order or architecture, linkers, modifications, quantity, purity target, analytical requirements and intended application.
Can Bio-Synthesis support scale-up and preclinical research?
Yes. Projects can be reviewed from research quantities through larger custom manufacturing, with scale-appropriate synthesis, purification, documentation and analytical planning.
How many epitopes can be combined in one construct?
There is no fixed maximum number of epitopes that can be incorporated into a multiepitope construct. Practical limits are determined by overall sequence length, amino acid composition, molecular architecture, modifications, purification strategy, and analytical feasibility. Long or compositionally difficult designs may be divided, branched, or assembled using alternative synthetic strategies.
Can B-cell and T-cell epitopes be combined?
Yes. B-cell, helper T-cell and cytotoxic T-cell epitopes can be combined, subject to sequence, linker, processing and synthesis feasibility review.
How should the epitopes be linked?
Flexible, rigid, protease-sensitive or application-specific linkers may be used. The choice depends on accessibility, processing, solubility and the intended biological readout.
Can multiepitope peptides be branched?
Yes. Defined branch points can display different epitope arms and may reduce the need for one very long linear sequence.

Recommended Reading

Selected background references for multiepitope peptide design, epitope engineering, vaccine constructs and peptide immunology.

  1. Skwarczynski M, Toth I. Peptide-based synthetic vaccines. Chemical Science. 2016.
  2. Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nature Reviews Drug Discovery. 2007.
  3. Nezafat N, et al. Designing an efficient multiepitope peptide vaccine using immunoinformatics and protein-interaction approaches. Computational Biology and Chemistry. 2016.
  4. De Groot AS, Rappuoli R. Genome-derived vaccines and the role of reverse vaccinology. Expert Review of Vaccines. 2004.
  5. Livingston BD, et al. A rational strategy to design multiepitope immunogens based on multiple T-lymphocyte epitopes. Journal of Immunology. 2002.

Note: References are provided for scientific background. Final multiepitope peptide constructs should be evaluated for epitope selection, linker design, construct architecture, solubility, manufacturability, purification and analytical characterization.

Why Choose Bio-Synthesis

Trusted by biotech leaders worldwide for over 45 years of delivering high-quality, fast, and scalable synthetic biology solutions.